MD Medical Group Reports Growth Across All Operational Indicators for Q2 2017
MD Medical Group Investments Plc (“MD Medical Group”, “MDMG” or the “Company” – LSE: MDMG), a leading Russian private healthcare provider, today announces its operating results for the second quarter and first half of 2017.
Key operational highlights for Q2 2017:
- Total IVF cycles increased 26% year-on-year (y-o-y) to 4,719
- Total deliveries increased 4% y-o-y to 1,716
- Total in-patient treatments increased 11% y-o-y to 15,435
- Total out-patient treatments increased 8% y-o-y to 373,255
Mark Kurtser, CEO of MD Medical Group, said:
“In the first half of 2017 we demonstrated strong operational performance and made another step forward in expanding our business in Russia.
“For the first six months of the year, we increased the number of IVF cycles by 23%, or 1,510 cycles, year-on-year. The number of deliveries grew 4% year-on-year despite a more challenging demographic situation. In-patient and out-patient treatments grew 8% and 9% year-on-year, respectively.
“This growth was mainly driven by the continued ramp-up of our state-of-the-art hospitals in Ufa, Novosibirsk, and Lapino, as well as the further development of other medical facilities across Russia.
“We continued to expand our leading network of healthcare facilities in line with the updated development strategy that we announced earlier this year. As planned, we started construction work on our new multidisciplinary hospital in Tyumen and opened our first clinic in this desirable location, which will help us gain experience and develop customer base in anticipation of the hospital opening. We are also continuing construction of our hospital in Samara, which will already be able to accept its first patients in early 2018. In June, we opened the Miscarriage Treatment Centre at PMC, which is unparalleled in Russia due to its technical capabilities and the outstanding experience of our highly professional team.
“We are pleased with the growth and successful implementation of our plans in the first half of the year. Thanks to these achievements and our even more ambitious plans, I am confident that we are well-positioned to remain the leader of the private healthcare market in Russia going forward.”
IVF
- In Q2 2017, total IVF cycles rose 26% y-o-y to 4,719.
- In H1 2017, total IVF cycles grew 23% y-o-y to 8,078.
- LFL[1] 7,773 IVF cycles were performed in H1 2017, up 18% y-o-y.
Deliveries
-
In Q2 2017, total deliveries increased 4% y-o-y to 1,716.
-
In H1 2017, total deliveries grew 4% y-o-y to 3,319.
In-patient treatments
- In Q2 2017, total in-patient treatments grew 11% y-o-y to 15,435, driven by:
- 9% increase in gynaecology in-patient treatments;
- 34% increase in in-patient days using other medical services.
- In H1 2017, total in-patient treatments grew 8% y-o-y to 30 311.
- LFL in-patient treatments increased 6% y-o-y in H1 2017 to 29,867.
Out-patient treatments
- In Q2 2017, the total number of out-patient treatments increased 8% y-o-y to 373,255, driven by:
- 7% increase in OBGYN out-patient treatments;
- 5% rise in paediatric out-patient visits;
- 12% increase in other medical services.
- In H1 2017, the total number of out-patient treatments increased 9% y-o-y to 737,271.
- LFL out-patient treatments increased 7% y-o-y in H1 2017 to 727,001.
|
|
LFL | ||||||||
|
|
2Q'17 |
2Q'16 |
p-o-p,% |
H1’17 | H1’16 |
y-o-y,% |
H1’17 |
H1’16 |
y-o-y,% |
|
Obstetrics and Gynaecology | |||||||||
|
Deliveries |
1,716 |
1,643 |
4% |
3,319 |
3,203 |
4% |
3,319 |
3,204 |
4% |
|
In-patient treatments (except deliveries) |
6,526 |
5,970 |
9% |
12,749 |
11,970 |
7% |
12,749 |
11,970 |
7% |
|
Out-patient treatments |
134,220 |
125,802 |
7% |
264,378 |
246,929 |
7% |
254,108 |
241,503 |
5% |
|
IVF | |||||||||
|
|
4,719 |
3,756 |
26% |
8,078 |
6,568 |
23% |
7,773 |
6,568 |
18% |
|
Paediatrics | |||||||||
|
In-patient treatments |
4,419 |
4,589 |
-4% |
9,375 |
9,393 |
0% |
9,375 |
9,395 |
0% |
|
Out-patient treatments |
105,624 |
100,293 |
5% |
208,318 |
192 556 |
8% |
208,318 |
192,660 |
8% |
|
Other medical services | |||||||||
|
In-patient treatments |
4,490 |
3,352 |
34% |
8,187 |
6,787 |
21% |
7,743 |
5,227 |
48% |
|
Out-patient treatments |
133,411 |
118,767 |
12% |
264,575 |
237,572 |
11% |
264,575 |
240,023 |
10% |
|
Total | |||||||||
|
Total deliveries |
1,716 |
1,643 |
4% |
3,319 |
3,203 |
4% |
3,319 |
3,203 |
4% |
|
Total IVF |
4,719 |
3,756 |
26% |
8,078 |
6,568 |
23% |
7,773 |
6,568 |
18% |
|
Total in-patient treatments |
15,435 |
13,911 |
11% |
30,311 |
28,150 |
8% |
29,867 |
28,150 |
6% |
|
Total out-patient treatments |
373,255 |
344,862 |
8% |
737,271 |
677,057 |
9% |
727,001 |
677,057 |
7% |
This announcement contains inside information.
For further information please contact:
|
Investors |
Media |
|
Elena Romanova
MD Medical Group Investments Plc
Tel: +7 495 331 4120 e.romanova@mcclinics.ru |
EM
Tom Blackwell: +7 919 102 9064 Sergii Pershyn: +1 929 855 8188
|
About MD Medical Group
MD Medical Group operates in the highly attractive Russian private healthcare service market and has a leading position in high-quality women's health and paediatrics. The company manages 33 modern healthcare facilities, including 4 hospitals and 29 outpatient clinics in Moscow and Moscow region, St. Petersburg, Ufa, Perm, Samara and Samara region, Irkutsk, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, Barnaul, Vladimir, and Tyumen.
The Company’s shares have been listed on the London Stock Exchange (LSE ticker “MDMG”) in the form of Global Depositary Receipts (GDRs) since 12 October 2012.
Forward-Looking Statements:
This press release contains forward looking statements, which are based on the Company’s current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company’s ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.
No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.